A detailed history of Price T Rowe Associates Inc transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,822,434 shares of PRTA stock, worth $58.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,822,434
Previous 4,237,404 9.79%
Holding current value
$58.9 Million
Previous $87.5 Million 26.88%
% of portfolio
0.01%
Previous 0.01%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$16.73 - $24.79 $6.94 Million - $10.3 Million
-414,970 Reduced 9.79%
3,822,434 $64 Million
Q2 2024

Aug 14, 2024

BUY
$19.54 - $26.15 $696,268 - $931,802
35,633 Added 0.85%
4,237,404 $87.5 Million
Q1 2024

May 15, 2024

SELL
$24.75 - $40.66 $880,605 - $1.45 Million
-35,580 Reduced 0.84%
4,201,771 $104 Million
Q4 2023

Feb 14, 2024

BUY
$32.31 - $52.32 $13.5 Million - $21.8 Million
417,338 Added 10.93%
4,237,351 $154 Million
Q3 2023

Nov 14, 2023

BUY
$47.3 - $70.6 $12.6 Million - $18.8 Million
266,245 Added 7.49%
3,820,013 $184 Million
Q2 2023

Aug 14, 2023

BUY
$48.26 - $78.59 $17 Million - $27.6 Million
351,475 Added 10.98%
3,553,768 $243 Million
Q1 2023

May 15, 2023

SELL
$46.97 - $58.27 $169,561 - $210,354
-3,610 Reduced 0.11%
3,202,293 $155 Million
Q4 2022

Feb 14, 2023

BUY
$52.05 - $65.0 $11.7 Million - $14.6 Million
223,962 Added 7.51%
3,205,903 $193 Million
Q3 2022

Nov 14, 2022

SELL
$25.16 - $60.63 $75.1 Million - $181 Million
-2,983,847 Reduced 50.02%
2,981,941 $181 Million
Q2 2022

Aug 15, 2022

SELL
$22.73 - $39.98 $3.36 Million - $5.92 Million
-147,954 Reduced 2.42%
5,965,788 $162 Million
Q1 2022

May 16, 2022

BUY
$30.27 - $49.22 $4.99 Million - $8.12 Million
164,881 Added 2.77%
6,113,742 $224 Million
Q4 2021

Feb 14, 2022

SELL
$42.11 - $73.26 $4.79 Million - $8.33 Million
-113,768 Reduced 1.88%
5,948,861 $294 Million
Q3 2021

Nov 15, 2021

BUY
$48.2 - $78.89 $11.5 Million - $18.9 Million
239,544 Added 4.11%
6,062,629 $432 Million
Q2 2021

Aug 16, 2021

BUY
$21.63 - $57.65 $54.3 Million - $145 Million
2,510,739 Added 75.8%
5,823,085 $299 Million
Q1 2021

May 17, 2021

BUY
$11.0 - $28.24 $36.3 Million - $93.1 Million
3,297,931 Added 22878.47%
3,312,346 $83.2 Million
Q4 2020

Feb 16, 2021

BUY
$10.12 - $13.94 $145,879 - $200,945
14,415 New
14,415 $173,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $723M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.